Compare BRFH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | SNTI |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 53.6M |
| IPO Year | N/A | N/A |
| Metric | BRFH | SNTI |
|---|---|---|
| Price | $2.67 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | 8.2K | ★ 4.5M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,574,000.00 | N/A |
| Revenue This Year | $37.56 | N/A |
| Revenue Next Year | $101.44 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $2.00 | $1.06 |
| 52 Week High | $6.08 | $5.10 |
| Indicator | BRFH | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 31.30 |
| Support Level | $2.53 | $1.15 |
| Resistance Level | $3.50 | $1.28 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 14.43 | 0.27 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.